Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Given Average Rating of “Hold” by Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has received an average rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $40.00.

A number of equities research analysts have commented on SNSE shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. Leerink Partners began coverage on Sensei Biotherapeutics in a research report on Monday. They set an “outperform” rating and a $50.00 target price on the stock. Finally, Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research report on Tuesday.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC lifted its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Trading Up 4.2%

NASDAQ SNSE opened at $31.64 on Thursday. The business’s 50-day moving average price is $28.78 and its two-hundred day moving average price is $16.43. Sensei Biotherapeutics has a 12 month low of $5.25 and a 12 month high of $36.76. The firm has a market capitalization of $42.40 million, a PE ratio of -1.90 and a beta of -0.10.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings results on Monday, March 30th. The company reported ($3.74) EPS for the quarter, beating analysts’ consensus estimates of ($4.81) by $1.07. As a group, analysts forecast that Sensei Biotherapeutics will post -2.77 earnings per share for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.